PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Jun 2

PMID 34066486

Citations 14

Authors

Hai Huang

Mee-Hyun Lee

Kangdong Liu

Zigang Dong

Zeayoung Ryoo

Myoung Ok Kim

Affiliations

Soon will be listed here.

Abstract

T-lymphokine-activated killer cell-originated protein kinase (TOPK, also known as PDZ-binding kinase or PBK) plays a crucial role in cell cycle regulation and mitotic progression. Abnormal overexpression or activation of TOPK has been observed in many cancers, including colorectal cancer, triple-negative breast cancer, and melanoma, and it is associated with increased development, dissemination, and poor clinical outcomes and prognosis in cancer. Moreover, TOPK phosphorylates p38, JNK, ERK, and AKT, which are involved in many cellular functions, and participates in the activation of multiple signaling pathways related to MAPK, PI3K/PTEN/AKT, and NOTCH1; thus, the direct or indirect interactions of TOPK make it a highly attractive yet elusive target for cancer therapy. Small molecule inhibitors targeting TOPK have shown great therapeutic potential in the treatment of cancer both in vitro and in vivo, even in combination with chemotherapy or radiotherapy. Therefore, targeting TOPK could be an important approach for cancer prevention and therapy. Thus, the purpose of the present review was to consider and analyze the role of TOPK as a drug target in cancer therapy and describe the recent findings related to its role in tumor development. Moreover, this review provides an overview of the current progress in the discovery and development of TOPK inhibitors, considering future clinical applications.

Citing Articles

CLDN6 triggers NRF2-mediated ferroptosis through recruiting DLG1/PBK complex in breast cancer.

Qi D, Lu Y, Qu H, Dong Y, Jin Q, Sun M Cell Death Dis. 2025; 16(1):122.

PMID: 39984471 PMC: 11845765. DOI: 10.1038/s41419-025-07448-9.

The Impact of BMI on PCOS Patients and Transcriptome Profiling and Bioinformatic Analysis of Granulosa Cells in PCOS Patients with High and Low BMI.

Tao P, Yan X, Li Y, Wang Z Reprod Sci. 2025; .

PMID: 39821799 DOI: 10.1007/s43032-024-01783-6.

The role of saponins on anti-cancer: The potential mechanism and molecular targets.

Ke F, Zhang R, Chen R, Guo X, Song C, Gao X Heliyon. 2024; 10(17):e37323.

PMID: 39296108 PMC: 11407946. DOI: 10.1016/j.heliyon.2024.e37323.

Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer.

Naik A, Lattab B, Qasem H, Decock J Mol Ther Oncol. 2024; 32(1):200768.

PMID: 38596293 PMC: 10876628. DOI: 10.1016/j.omton.2024.200768.

Bruceine D and Narclasine inhibit the proliferation of breast cancer cells and the prediction of potential drug targets.

Chen X, Li H PLoS One. 2024; 19(1):e0297203.

PMID: 38215156 PMC: 10786365. DOI: 10.1371/journal.pone.0297203.

References

Herbert K, Puliyadi R, Prevo R, Rodriguez-Berriguete G, Ryan A, Ramadan K . Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress. Cell Death Differ. 2020; 28(4):1333-1346. PMC: 8027845. DOI: 10.1038/s41418-020-00655-1. View

Kang N, Lee K, Kim B, Bode A, Lee H, Heo Y . Coffee phenolic phytochemicals suppress colon cancer metastasis by targeting MEK and TOPK. Carcinogenesis. 2011; 32(6):921-8. PMC: 3106432. DOI: 10.1093/carcin/bgr022. View

Cote S, Simard C, Lemieux R . Regulation of growth-related genes by interleukin-6 in murine myeloma cells. Cytokine. 2002; 20(3):113-20. DOI: 10.1006/cyto.2002.1988. View

Lee Y, Park J, Oh S . TOPK promotes epithelial-mesenchymal transition and invasion of breast cancer cells through upregulation of TBX3 in TGF-β1/Smad signaling. Biochem Biophys Res Commun. 2019; 522(1):270-277. DOI: 10.1016/j.bbrc.2019.11.104. View

Park J, Jeong Y, Won H, Choi S, Park J, Oh S . Activation of TOPK by lipopolysaccharide promotes induction of inducible nitric oxide synthase through NF-κB activity in leukemia cells. Cell Signal. 2014; 26(5):849-56. DOI: 10.1016/j.cellsig.2014.01.004. View

Peterson D, Lee J, Lei X, Forrest W, Davis D, Jackson P . A chemosensitization screen identifies TP53RK, a kinase that restrains apoptosis after mitotic stress. Cancer Res. 2010; 70(15):6325-35. DOI: 10.1158/0008-5472.CAN-10-0015. View

Song X, Yin S, Zhang E, Fan L, Ye M, Zhang Y . Glycycoumarin exerts anti-liver cancer activity by directly targeting T-LAK cell-originated protein kinase. Oncotarget. 2016; 7(40):65732-65743. PMC: 5323188. DOI: 10.18632/oncotarget.11610. View

He F, Yan Q, Fan L, Liu Y, Cui J, Wang J . PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma. Hum Pathol. 2009; 41(3):415-24. DOI: 10.1016/j.humpath.2009.05.016. View

Hu F, Gartenhaus R, Eichberg D, Liu Z, Fang H, Rapoport A . PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21. Oncogene. 2010; 29(40):5464-74. DOI: 10.1038/onc.2010.275. View

10.

Park J, Lin M, Nishidate T, Nakamura Y, Katagiri T . PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res. 2006; 66(18):9186-95. DOI: 10.1158/0008-5472.CAN-06-1601. View

11.

Li Y, Yang Z, Li W, Xu S, Wang T, Wang T . TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun. Oncotarget. 2016; 7(6):6748-64. PMC: 4872746. DOI: 10.18632/oncotarget.6826. View

12.

Smorodinsky-Atias K, Goshen-Lago T, Goldberg-Carp A, Melamed D, Shir A, Mooshayef N . Intrinsically active variants of Erk oncogenically transform cells and disclose unexpected autophosphorylation capability that is independent of TEY phosphorylation. Mol Biol Cell. 2015; 27(6):1026-39. PMC: 4791124. DOI: 10.1091/mbc.E15-07-0521. View

13.

Park J, Nishidate T, Nakamura Y, Katagiri T . Critical roles of T-LAK cell-originated protein kinase in cytokinesis. Cancer Sci. 2009; 101(2):403-11. PMC: 11159100. DOI: 10.1111/j.1349-7006.2009.01400.x. View

14.

DeNicola G, Martin E, Chaikuad A, Bassi R, Clark J, Martino L . Mechanism and consequence of the autoactivation of p38α mitogen-activated protein kinase promoted by TAB1. Nat Struct Mol Biol. 2013; 20(10):1182-90. PMC: 3822283. DOI: 10.1038/nsmb.2668. View

15.

Xi G, Hu X, Wu B, Jiang H, Young C, Pang Y . Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells. Cancer Lett. 2011; 307(2):141-8. DOI: 10.1016/j.canlet.2011.03.026. View

16.

Ayllon V, OConnor R . PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response. Oncogene. 2006; 26(24):3451-61. DOI: 10.1038/sj.onc.1210142. View

17.

Zheng M, Luan S, Gao S, Cheng L, Hao B, Li J . Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase. Oncotarget. 2017; 8(24):39143-39153. PMC: 5503601. DOI: 10.18632/oncotarget.16609. View

18.

Mao P, Bao G, Wang Y, Du C, Yu X, Guo X . PDZ-Binding Kinase-Dependent Transcriptional Regulation of CCNB2 Promotes Tumorigenesis and Radio-Resistance in Glioblastoma. Transl Oncol. 2019; 13(2):287-294. PMC: 6931196. DOI: 10.1016/j.tranon.2019.09.011. View

19.

Dougherty J, Garcia A, Nakano I, Livingstone M, Norris B, Polakiewicz R . PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase. J Neurosci. 2005; 25(46):10773-85. PMC: 6725850. DOI: 10.1523/JNEUROSCI.3207-05.2005. View

20.

Shih M, Chen J, Wu Y, Jan Y, Yang B, Lu P . TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene. 2011; 31(19):2389-400. DOI: 10.1038/onc.2011.419. View